Unusual onset of venous thromboembolism and heparin-induced thrombocytopenia in a patient with essential thrombocythemia

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 1, 2010, Pages 85-90

  Lapecorella, Mario ^a   Lucchesi, Alessandro ^a   Di Ianni, Mauro ^a   Napolitano, Mariasanta ^a   Coletti, Gino ^a   Di Leonardo, Gabriella ^a   Dell'Orso, Luigi ^a   Barnabei, Remo ^a   Mariani, Guglielmo ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Essential thrombocythemia; Heparin induced thrombocytopenia; Pneumocystis carinii; Venous thromboembolism

Indexed keywords

ANTITHROMBIN; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CEFOTAXIME; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; D DIMER; FIBRINOGEN; FONDAPARINUX; HEMOGLOBIN; HEPARIN; HOMOCYSTEINE; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; ARTICLE; BONE MARROW EXAMINATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DEEP VEIN THROMBOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ECHOGRAPHY; FEMALE; FEVER; FIBEROPTIC BRONCHOSCOPY; FIBRINOGEN BLOOD LEVEL; GENE MUTATION; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEG SWELLING; LEUKOCYTE COUNT; LUNG EMBOLISM; LYMPHOCYTE COUNT; MEAN CORPUSCULAR VOLUME; NEUTROPHIL COUNT; NORMOCHROMIC NORMOCYTIC ANEMIA; PARTIAL THROMBOPLASTIN TIME; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTHROMBIN TIME; REMISSION; THORAX RADIOGRAPHY; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRACHEOBRONCHIAL TOILET; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; FEMALE; HEPARIN; HUMANS; INCIDENTAL FINDINGS; PLATELET FACTOR 4; PNEUMONIA, PNEUMOCYSTIS; POLYSACCHARIDES; PULMONARY EMBOLISM; THROMBOCYTHEMIA, ESSENTIAL; THROMBOCYTOPENIA; THROMBOPHLEBITIS; WARFARIN;

EID: 75649091916     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832f2b08     Document Type: Article

References (27)

1. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem-cell and probable clonal origin of the disease. N Engl J Med 1976; 295:913-916.
2. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004; 22:247-306.
3. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-1061.
4. Suá rez Conde I, Peteiro C, Pereiro Ferreiró s MM, Toribio J. Cutaneous vasculitis revealing essential thrombocythemia. Dermatology 2002; 205:75-76.
5. Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 2006; 32:589-604.
6. Koudstaal PJ, Koudstaal A. Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin. Semin Thromb Hemost 1997; 23:365-370.
7. Risch L, Pihan H, Zeller C, Huber AR. ET gets HIT-thrombocytotic heparin-induced thrombocytopenia (HIT) in a patient with essential thrombocythemia (ET). Blood Coagul Fibrinolysis 2000; 11:663-667.
8. Lapecorella M, Tabilio A, Lucchesi A, Napolitano M, Colagrande M, Di Ianni, et al. Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment. Blood Coagul Fibrinolysis 2008; 19:453-457.
9. Di Ianni M, Moretti L, Del Papa B, Gaozza E, Bell AS, Falzetti F, et al. A microelectronic DNA chip detects the V617F JAK-2 mutation in myeloproliferative disorders. Leukemia 2006; 20:1895-1897.
10. Pagano L, Fianchi L, Mele L, Girmenia C, Offidani M, Ricci P, et al. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol 2002; 117:379-386.
11. Steele C, Shellito JE, Kolls JK. Immunity against the opportunistic fungal pathogen Pneumocystis. Med Mycol 2005; 43:1-19.
12. Laursen AL, Obel N, Rungby J, Andersen PL. Phagocytosis and stimulation of the respiratory burst in neutrophils by Pneumocystis carinii. J Infect Dis 1993; 168:1466-1471.
13. Wang J, Gigliotti F, Bhagwat SP, Maggirwar SB, Wright TW. Pneumocystis stimulates MCP-1 production by alveolar epithelial cells through a JNKdependent mechanism. Am J Physiol Lung Cell Mol Physiol 2007; 292:L1495-L1505.
14. Wolach B, Gavrieli R, Manor Y, Lishner M. Leukocyte function in chronic myeloproliferative disorders. Blood Cells Mol Dis 1998; 24:544-551.
15. Burgaleta C, Gonzá lez N, Cé sar J. Increased CD11/CD18 expression and altered metabolic activity on polymorphonuclear leukocytes from patients with polycythemia vera and essential thrombocythemia. Acta Haematol 2002; 108:23-28.
16. Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008; 26:2732-2736.
17. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007; 109:2446-2452.
18. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96:4261-4266.
19. Afshar-Kharghan V, Thiagarajan P. Leukocyte adhesion and thrombosis. Curr Opin Hematol 2006; 13:34-39.
20. Kelton JG, Smith JW, Warkentin TE, Hayward CP, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83:3232-3239.
21. Linkins LA, Warkentin TE. The approach to heparin-induced thrombocytopenia. Semin Respir Crit Care Med 2008; 29:66-74.
22. Harenberg J, Jö rg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 2004; 89:1017-1018.
23. Spectre G, Kalish Y, Schliamser L, Varon D. Heparin-induced thrombocytopenia in myeloproliferative disorders: a rare or underdiagnosed complication? Am J Hematol 2008; 83:420-423.
24. Hayashi T, Suyama Y, Kaneko M, Okamura J, Nakao Y, Nonaka Y, Nomura T. Heparin-induced thrombocytopenia and thrombosis in a patient with polycythemia vera. Intern Med 2004; 43:587-589.
25. Houston DS. Heparin-induced thrombocytopenia without thrombocytopenia in a patient with essential thrombocythemia. Am J Hematol 2000; 65:331-332.
26. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006; 91:169-175.
27. Hattori N, Fukuchi K, Nakashima H, Maeda T, Adachi D, Saito B, et al. Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation. Int J Hematol 2008; 88:181-188.